|
Volumn 263, Issue 5145, 1994, Pages 380-384
|
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors
a a a a a a a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIVIRUS AGENT;
CYCLIC UREA DERIVATIVE;
PROTEINASE;
PROTEINASE INHIBITOR;
UNCLASSIFIED DRUG;
ARTICLE;
BIOAVAILABILITY;
DRUG DESIGN;
ENZYME INHIBITION;
HUMAN IMMUNODEFICIENCY VIRUS;
NONHUMAN;
ORAL DRUG ADMINISTRATION;
PRIORITY JOURNAL;
X RAY CRYSTALLOGRAPHY;
ADMINISTRATION, ORAL;
ANIMAL;
AZEPINES;
BINDING SITES;
BIOLOGICAL AVAILABILITY;
CELL LINE;
CRYSTALLOGRAPHY, X-RAY;
DOGS;
DRUG DESIGN;
DRUG EVALUATION, PRECLINICAL;
HIV PROTEASE;
HIV PROTEASE INHIBITORS;
HIV-1;
HYDROGEN BONDING;
MODELS, MOLECULAR;
MOLECULAR CONFORMATION;
MOLECULAR WEIGHT;
RATS;
RECOMBINANT PROTEINS;
SUPPORT, NON-U.S. GOV'T;
UREA;
VIRUS REPLICATION;
|
EID: 0028057975
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.8278812 Document Type: Article |
Times cited : (923)
|
References (65)
|